AIDS Research and Therapy, 2017 Background As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and ...
Marianne Harris +5 more
doaj +1 more source
Darunavir Baskılanmış Phema Temelli Mikrokriyojellerin Hazırlanması ve Salım Kinetiğinin İncelenmesi [PDF]
, 2022 Darunavir (D.V) is a powerful Antiretroviral drug used to treat infections with the human immunodeficiency virus (HIV). Acquired immunodeficiency syndrome (AIDS) is the most advanced stage of HIV infection.
Şafak, İsmet
core
Evaluation of the Side Effects of Antiretroviral Treatment
Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018 Introduction: The frequency of antiretroviral therapy (ART)-induced side effects varies in HIV-infected patients. In this study, we aimed to compare drug-induced side effects developing in patients receiving different ART regimens. Materials and Methods:
Sedef BAŞGÖNÜL +2 more
doaj +1 more source
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals [PDF]
, 2014 OBJECTIVES Darunavir is a protease inhibitor that is administered with low-dose ritonavir to enhance its bioavailability. It is prescribed at standard dosage regimens of 600/100 mg twice daily in treatment-experienced patients and 800/100 mg once daily ...
Lubomirov, R +31 more
core +1 more source
HIV-1 Protease: Structural Perspectives on Drug Resistance
Viruses, 2009 Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms
Irene T. Weber, Johnson Agniswamy
doaj +1 more source
Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow +4 more
wiley +1 more source
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: A population pharmacokinetic approach [PDF]
, 2016 Objectives: Treatment of HIV/TB coinfection is challenging due to potent drug-drug interactions between antiretrovirals and rifampicin. The effect of rifampicin on darunavir/ritonavir has not been studied. Population pharmacokinetic modelling was applied
Boffito, M +5 more
core +2 more sources
Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women [PDF]
, 2017 Item does not contain fulltextThe dosage of darunavir/ritonavir is 800/100 mg once daily for treatment-naive patients or treatment-experienced patients with no prior darunavir resistance associated mutations, and 600/100 mg twice daily for treatment ...
Burger, D.M. +7 more
core
Análise quimico-farmacêutica de Darunavir etanolato em comprimidos e de seu complexo de inclusão [PDF]
, 2015 The work aimed the formation of complex darunavir:β-cyclodextrin and the study of the consequences of complexation, as well as development and validation of analytical methods for qualitative and quantitative determination of darunavir in tablet (free ...
Kogawa, Ana Carolina
core +2 more sources
Development of qualitative analytical methods for monitoring darunavir tablets [PDF]
, 2013 Darunavir is a protease inhibitor used in the treatment of HIV infection. It is a pillar of the drug cocktail for patients diagnosed with the virus. Quality control in the pharmaceutical industry, to verify the content of active substance and study the ...
Salgado, Hérida Regina Nunes [UNESP] +1 more
core